JP7763753B2 - アザキノリン化合物およびその使用 - Google Patents

アザキノリン化合物およびその使用

Info

Publication number
JP7763753B2
JP7763753B2 JP2022519331A JP2022519331A JP7763753B2 JP 7763753 B2 JP7763753 B2 JP 7763753B2 JP 2022519331 A JP2022519331 A JP 2022519331A JP 2022519331 A JP2022519331 A JP 2022519331A JP 7763753 B2 JP7763753 B2 JP 7763753B2
Authority
JP
Japan
Prior art keywords
amino
methyl
cyclohexyl
trans
naphthyridin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022519331A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022550353A5 (cg-RX-API-DMAC7.html
JP2022550353A (ja
Inventor
リー,リン
ダイ,シュアン
ドーレ,マイケル
ジャスティン グー,シャンジュ
クン チン リウ,ケビン
イェウン フランキー マク,シン
ミ,ユアン
オヤン,カウンド
パピヨン,ジュリエン
キー,ウェイ(ヴィッキー)
ヤン,シャオシャオ
ユ,チェンティアン
ユー(ジェフ) チャン,ジ
ザオ,キハオ
Original Assignee
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2022550353A publication Critical patent/JP2022550353A/ja
Publication of JP2022550353A5 publication Critical patent/JP2022550353A5/ja
Application granted granted Critical
Publication of JP7763753B2 publication Critical patent/JP7763753B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022519331A 2019-09-26 2020-09-24 アザキノリン化合物およびその使用 Active JP7763753B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2019108296 2019-09-26
CNPCT/CN2019/108296 2019-09-26
PCT/CN2020/117487 WO2021057853A1 (en) 2019-09-26 2020-09-24 Aza-quinoline compounds and uses thereof

Publications (3)

Publication Number Publication Date
JP2022550353A JP2022550353A (ja) 2022-12-01
JP2022550353A5 JP2022550353A5 (cg-RX-API-DMAC7.html) 2023-08-22
JP7763753B2 true JP7763753B2 (ja) 2025-11-04

Family

ID=75166744

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022519331A Active JP7763753B2 (ja) 2019-09-26 2020-09-24 アザキノリン化合物およびその使用

Country Status (11)

Country Link
US (2) US12544374B2 (cg-RX-API-DMAC7.html)
EP (1) EP4034535B1 (cg-RX-API-DMAC7.html)
JP (1) JP7763753B2 (cg-RX-API-DMAC7.html)
KR (1) KR102889562B1 (cg-RX-API-DMAC7.html)
CN (1) CN114746414B (cg-RX-API-DMAC7.html)
AU (1) AU2020355837B2 (cg-RX-API-DMAC7.html)
CA (1) CA3150284A1 (cg-RX-API-DMAC7.html)
DK (1) DK4034535T3 (cg-RX-API-DMAC7.html)
ES (1) ES3067468T3 (cg-RX-API-DMAC7.html)
IL (1) IL291499B2 (cg-RX-API-DMAC7.html)
WO (1) WO2021057853A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK4034535T3 (da) 2019-09-26 2026-04-07 Novartis Ag Aza-quinolinforbindelser og anvendelser deraf
AR123185A1 (es) * 2020-08-10 2022-11-09 Novartis Ag Compuestos y composiciones para inhibir ezh2
AR128015A1 (es) * 2021-12-16 2024-03-20 Transthera Sciences Nanjing Inc Inhibidor de cdk9 y uso del mismo
CN117384153A (zh) * 2022-07-12 2024-01-12 上海赛岚生物科技有限公司 一类甲基转移酶抑制剂及其用途
CN118515653B (zh) * 2024-07-23 2024-12-10 西湖制药(杭州)有限公司 一种ezh2特异性抑制剂及其制备方法和用途
CN118598873B (zh) * 2024-08-07 2024-11-19 艾斯拓康生物医药(天津)有限公司 一种手性的氮杂-喹啉类化合物的制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018500342A (ja) 2014-12-23 2018-01-11 ノバルティス アーゲー トリアゾロピリミジン化合物およびその使用
JP2018522874A (ja) 2015-06-30 2018-08-16 グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッドGlaxosmithkline Intellectual Property (No.2) Limited Zesteホモログ2エンハンサー阻害剤
JP2019522049A (ja) 2016-06-20 2019-08-08 ノバルティス アーゲー トリアゾロピリジン化合物及びその使用
JP2019524872A (ja) 2016-06-20 2019-09-05 ノバルティス アーゲー 癌の治療に有用なイミダゾピリミジン化合物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2779780A (en) 1955-03-01 1957-01-29 Du Pont 1, 4-diamino-2, 3-dicyano-1, 4-bis (substituted mercapto) butadienes and their preparation
EP0647450A1 (en) 1993-09-09 1995-04-12 BEHRINGWERKE Aktiengesellschaft Improved prodrugs for enzyme mediated activation
JP2002532415A (ja) 1998-12-16 2002-10-02 ワーナー−ランバート・カンパニー Mek阻害剤による関節炎の治療
AU7349801A (en) 2000-07-19 2002-01-30 Warner Lambert Co Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
CA2478065C (en) 2002-03-08 2013-01-08 Eisai Co. Ltd. Macrocyclic compounds useful as pharmaceuticals
SG2013013339A (en) 2002-03-13 2014-12-30 Array Biopharma Inc N3 alkylated benzimidazole derivatives as mek inhibitors
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
MX2008002114A (es) 2005-07-21 2008-04-17 Ardea Biosciences Inc Inhibidores de n-(arilamino)-sulfonamida de mek.
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
BRPI0816769A2 (pt) 2007-09-12 2016-11-29 Hoffmann La Roche combinações de compostos inibidores de fosfoinositida 3-cinase e agentes quimioterapêuticos, e métodos de uso
WO2009055730A1 (en) 2007-10-25 2009-04-30 Genentech, Inc. Process for making thienopyrimidine compounds
US8168784B2 (en) 2008-06-20 2012-05-01 Abbott Laboratories Processes to make apoptosis promoters
WO2014155301A1 (en) 2013-03-26 2014-10-02 Piramal Enterprises Limited Substituted bicyclic compounds as inhibitors of ezh2
MX2019004950A (es) 2016-10-28 2019-09-26 Icahn School Med Mount Sinai Composiciones y metodos para tratar el cancer mediado por el potenciador del homologo zeste 2.
DK4034535T3 (da) 2019-09-26 2026-04-07 Novartis Ag Aza-quinolinforbindelser og anvendelser deraf

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018500342A (ja) 2014-12-23 2018-01-11 ノバルティス アーゲー トリアゾロピリミジン化合物およびその使用
JP2018522874A (ja) 2015-06-30 2018-08-16 グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッドGlaxosmithkline Intellectual Property (No.2) Limited Zesteホモログ2エンハンサー阻害剤
JP2019522049A (ja) 2016-06-20 2019-08-08 ノバルティス アーゲー トリアゾロピリジン化合物及びその使用
JP2019524872A (ja) 2016-06-20 2019-09-05 ノバルティス アーゲー 癌の治療に有用なイミダゾピリミジン化合物

Also Published As

Publication number Publication date
CN114746414B (zh) 2024-10-18
EP4034535A1 (en) 2022-08-03
CN114746414A (zh) 2022-07-12
US20260076968A1 (en) 2026-03-19
KR20220070229A (ko) 2022-05-30
US12544374B2 (en) 2026-02-10
AU2020355837B2 (en) 2025-10-02
IL291499B1 (en) 2025-04-01
WO2021057853A1 (en) 2021-04-01
KR102889562B1 (ko) 2025-11-24
AU2020355837A1 (en) 2022-02-24
IL291499B2 (en) 2025-08-01
DK4034535T3 (da) 2026-04-07
CA3150284A1 (en) 2021-04-01
US20220280509A1 (en) 2022-09-08
ES3067468T3 (en) 2026-05-22
JP2022550353A (ja) 2022-12-01
EP4034535B1 (en) 2026-03-04
EP4034535A4 (en) 2023-11-22
IL291499A (en) 2022-05-01

Similar Documents

Publication Publication Date Title
JP6736559B2 (ja) トリアゾロピリミジン化合物およびその使用
KR102889562B1 (ko) 아자-퀴놀린 화합물 및 그의 용도
EP3472161B1 (en) Triazolopyridine compounds and uses thereof
JP2019524872A (ja) 癌の治療に有用なイミダゾピリミジン化合物
JP7768880B2 (ja) Ezh2を阻害するためのキノリン化合物および組成物
JP2022539208A (ja) チロシンキナーゼ非受容体1(tnk1)阻害剤およびその使用
HK40077297A (en) Aza-quinoline compounds and uses thereof
HK40077297B (en) Aza-quinoline compounds and uses thereof
HK40080941B (en) Quinoline compounds and compositions for inhibiting ezh2 as a treatment for cancer diseases
HK40080941A (en) Quinoline compounds and compositions for inhibiting ezh2 as a treatment for cancer diseases
HK40117897A (en) Compounds and compositions for inhibiting ezh2

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230810

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230810

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240730

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240731

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241029

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250414

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250513

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250812

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250924

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251022

R150 Certificate of patent or registration of utility model

Ref document number: 7763753

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150